Skip to main content

Advertisement

Table 4 Univariate subgroups analysis of overall survival

From: Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

  FOLFOX-4 TOPOTECAN  
  No. patients No. events Median PFS (95% CI) No. patients No. events Median PFS (95% CI) P
Site of metastasis
  Only abdominal 11 11 5.0 (1.3–14.6) 20 18 10.4 (2.9–25.0) 0.166
  Abdominal+extra-abdominal 18 17 8.2 (2.4–16.7) 6 6 12.7 (2.7–23.4) 0.919
P    0.771    0.492  
Lines of previous treatments
  ≤ 4 15 15 10.2 (1.3–16.7) 20 18 10.5 (2.7–25.0) 0.057
  > 4 14 13 5.5 (2.4–14.6) 6 6 10.4 (2.9–16.2) 0.789
P    0.753    0.206  
Baseline NLR
  < 3 13 12 14.6 (3.8–22.9) 20 18 10.4 (4.9–23.4) 0.870
  ≥ 3 15 15 5.4 (1.2–10.2) 5 5 2.9 (1.5–15.0) 0.858
P    0.013    0.051  
Baseline PLR
  < 210 13 12 13.0 (1.8–18.9) 18 16 10.5 (4.9–23.3) 0.514
  ≥ 210 15 15 5.6 (1.3–14.1) 7 7 10.0 (1.5–15.0) 0.660
P    0.275    0.061  
  1. Abbreviations. FOLFOX-4 oxaliplatin, leucovorin, and 5-fluorouracil; number; CI confidence interval, NLR neutrophils-to-lymphocyte ratio, OS overall survival, PLR platelet-to-lymphocyte ratio